Allison A. Johnson, Christophe Marchand and Yves Pommier Pages 1059 - 1077 ( 19 )
AIDS is currently treated with a combination therapy of reverse transcriptase and protease inhibitors. Recently, the FDA approved a drug targeting HIV-1 entry into cells. There are currently no FDA approved drugs targeting HIV-1 integrase, though many scientists and drug companies are actively in pursuit of clinically useful integrase inhibitors. The objective of this review is to provide an update on integrase inhibitors reported in the last two years, including two novel inhibitors in early clinical trials, recently developed hydroxylated aromatics, natural products, peptide, antibody and oligonucleotide inhibitors. Additionally, the proposed mechanism of diketo acid inhibition is reviewed.
hiv-1 integrase, diketo acids, hiv inhibitors, aids, integrase inhibitors
Laboratory of MolecularPharmacology, CCR, NCI, NIH, Building 37, Room 5068, Bethesda, MD20892, USA